First Bio-Similar Drug Passed FDA's Stringent Evaluation Procedure

March 7, 2015 7:53 AM

25 0

The Food and Drug Administration has sanction the first supposed biosimilar drug for utilization in the United States, preparing for less lavish choices to a whole class of complex and expensive medications.

The medication, called Zarxio, delivered by Sandoz, is utilized to help avert infections in cancer patients undergoing chemotherapy. It is a close duplicate of a current medication called Neupogen, made by Amgen. It was approved in Europe in 2009 as Zarzio yet has not been utilized in the United Sta...

Read more

To category page